LB Pharmaceuticals (LBRX) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
LB Pharmaceuticals (LBRX) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 153.4% versus a loss of 67.4%. LB Pharmaceuticals is the larger company by market cap ($1.26 billion vs $1.21 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LBRX | MLYS |
|---|---|---|
| Share price | $38.85 | $13.66 |
| Market cap | $1.26B | $1.21B |
| 1-day change | -2.97% | -3.53% |
| YTD return | +74.53% | -62.36% |
| 1-year return | +153.42% | -67.38% |
| EPS (TTM) | $-1.12 | $-4.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-25.20M | $-154.65M |
| 52-week high | $50.16 | $44.13 |
| 52-week low | $15.55 | $13.57 |
| Distance from 52-week high | -22.55% | -69.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +49.29% | +218.89% |
| Average volume | 373.16K | 1.55M |
| Shares outstanding | 32.36M | 88.56M |
| Employees | 62 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LBRX has outperformed MLYS by 220.8 percentage points over the past year.
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 62 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
LBRX vs MLYS FAQ
Which is bigger, LB Pharmaceuticals or Mineralys Therapeutics?
LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.26B compared with $1.21B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, LBRX or MLYS?
LBRX returned +153.42% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are LB Pharmaceuticals and Mineralys Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.